On September 30, 2024, Novo Nordisk A/S, a leading global healthcare company, reported progress on its share repurchase program. The program, which began on February 6, 2024, aims to buy back shares worth up to DKK 20 billion over a 12-month period. As part of this initiative, a specific tranche was initiated on August 7, 2024, with the intention to repurchase up to DKK 2.4 billion in B shares by November 4, 2024. Since the last announcement on September 23, 2024, Novo Nordisk has purchased an additional 205,935 B shares at an average price of DKK 835.48, amounting to DKK 172,706,664. This brings the total repurchased under the program to 1,604,058 B shares at an average price of DKK 880.84, totaling DKK 11,161,264,179. The company now holds 13,999,815 B shares as treasury shares, representing 0.3% of the share capital. Novo Nordisk, established in 1923 and headquartered in Denmark, is committed to combating serious chronic diseases and employs approximately 69,000 people worldwide.

On September 30, 2024, Novo Nordisk A/S, a leading global healthcare company, reported progress on its share repurchase program. The program, which began on February 6, 2024, aims to buy back shares worth up to DKK 20 billion over a 12-month period. As part of this initiative, a specific tranche was initiated on August 7, 2024, with the intention to repurchase up to DKK 2.4 billion in B shares by November 4, 2024. Since the last announcement on September 23, 2024, Novo Nordisk has purchased an additional 205,935 B shares at an average price of DKK 835.48, amounting to DKK 172,706,664. This brings the total repurchased under the program to 1,604,058 B shares at an average price of DKK 880.84, totaling DKK 11,161,264,179. The company now holds 13,999,815 B shares as treasury shares, representing 0.3% of the share capital. Novo Nordisk, established in 1923 and headquartered in Denmark, is committed to combating serious chronic diseases and employs approximately 69,000 people worldwide.